AI-Enabled Medtech and the Future of Diagnostics

Jeff Champagne – Senior Director, MedTech Solutions, EPAM Continuum 

Jeff Champagne, based in Greater Boston, brings 16 years of experience in medical device R&D innovation and 23 years of sales and marketing leadership in healthcare and innovative ecosystems.  Jeff brings solid experiences in both well-established and start-up organizations, with strong bias for growth.  He has developed relationships with business leaders and coached his clients to improve their productivity and profitability by defining roadmaps, navigating obstacles, and reaching objectives to speed up commercialization efforts.   

Jeff is Board Vice Chair at LifeSciencesNY, Syracuse, NY, Board Advisor at M2D2 Massachusetts Medical Device Development Center at UMass-Lowell, Lowell, MA, and is on the Life Science Screening Committee for Boston Harbor Angels.  Champagne has also recently been added as a Board Advisor to Medical Device Group (MDG) Boston. Jeff served this past two years as a judge for the MedTech Innovator competition. He is currently Senior Director of Client Engagement at EPAM Systems in Boston. 

Champagne earned a Bachelor of Fine Arts in Illustration, Visual Communication Design degree from the University of Hartford Art School and an MBA in Marketing, Entrepreneurial Studies from the University of Hartford, West Hartford, CT.

Anastasia Christianson, PhD – Managing Principal, Business Consulting, Clinical Informatics 

Anastasia is a strategic, visionary leader with an established track record of building and leading multidisciplinary, global Informatics and IS/IT teams, driving change and simplification and delivering value through innovation. Over 20 years’ experience in the biotechnology and pharmaceutical industry working in both Discovery and Development leading projects, managing complex portfolios, driving change programs, identifying opportunities for strategic initiatives, and translating scientific and medical questions into innovative solutions. Areas of particular strength include: strategy development and implementation, translational medicine, biomedical and health informatics, evidence-based decision makings, data and decision science, and “Big Data” exploitation

Alyssa Abo, MD – VP of Clinical Innovation, DeepSight Technology 

Dr. Alyssa Abo is a pioneering physician executive with over 20 years of experience in MedTech and digital health, recognized for integrating advanced technologies to transform clinical medicine. She pushes the boundaries of innovation by leveraging her medical, technological, and business background to deliver scalable, impactful solutions that drive patient-centered care, improve outcomes, and elevate healthcare globally. Dr. Abo’s thought leadership in medical imaging, artificial intelligence, real-world data applications, and pediatric technologies has set new standards across the healthcare ecosystem. Dr. Abo is frequently invited as a speaker, panelist, and podcast guest, to discuss emerging tech and entrepreneurship.

Dr. Abo is the VP of Clinical Innovation at DeepSight Technology, while also serving as a Board Director at Picterus and AcQumen, and Real-World Evidence Advisor for Stanford Biodesign’s Impact1 program. Her leadership has been instrumental in shaping industry-wide policies adopted by organizations such as the American Academy of Pediatrics and the American Institute for Ultrasound in Medicine.

Dr. Abo holds degrees in Biomedical Engineering from the University of Pennsylvania, an MD from the American Program at Tel Aviv University, and an MBA from George Washington University, with advanced clinical training at Yale-New Haven and Boston Children’s Hospitals.

Wilson To, MD – PhD, VP, Global Strategy & BD, Healthcare Informatics

Wilson To is a strategy and business executive for Royal Philips, a leading global healthcare technology company. He leads strategy development for the Enterprise Informatics division 

He oversees key modernization and transformation efforts across the Philips HealthSuite Platform to enable the informatics needed to support clinicians in making the precision diagnoses to deliver personalized therapies, to aid the patient’s recovery from the hospital to the home, and to support people to live healthier lifestyles and prevent disease – all with the goal to improve the lives of 2.5 billion people a year by 2025 through meaningful innovation.

Prior to joining Philips, Wilson was the head of healthcare at Amazon Web Services, the cloud computing division of Amazon, where he built out industry-specific cloud technologies and go-to-market initiatives that enabled thousands of HCLS organizations to address the global pandemic, health equity crisis, and power the personalization of medicine. Within Amazon, he also led research and product development efforts within its Grand Challenges organization. He also spent the earlier parts of his career leading product management at other technology organizations, both at Caradigm (Microsoft-GE Healthcare JV) and IQVIA (Quintiles-IMS Health).

Wilson obtained his PhD in Integrative Pathobiology from the University of California- Davis, where he led several scientific investigations and published discoveries in microcirculatory systems related to vascular diseases using computer-assisted intravital microscopy. He continues to remain actively involved in academic community, both as part of the National Advisory Board for UC Davis Health and as a Graduate Faculty Scholar for University of Central Florida. His work in global health driving AI-enabled point-of-care technologies to support early screening of diseases have been recognized by international leaders.